50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
“Our mission is to address the significant need for new treatments in cancers of the bone in children and young adults.”In use 2025 – now·1 sighting·SEC Form S-1, filed 2025-08-0489% match
“Our mission is to improve the lives of patients by developing novel therapeutics to treat some of the most devastating types of cancer.”In use 2026 – now·1 sighting·SEC Form 10-K/A, filed 2026-06-0270% match
“Our mission is to develop new medicines to treat and cure patients with solid tumors using our next generation TIL therapy approach.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2270% match
“Our mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest unmet medical need – aggressive cancers where current therapies are inadequate.”In use 2016 – now·1 sighting·SEC Form 10-K, filed 2016-02-2969% match
“Our mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-02-2169% match
“Our mission is to develop next-generation, potentially curative cell therapies for people with cancer.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-1269% match
“Our mission is to develop novel therapies by utilizing our disease-agnostic platform to address areas of high unmet medical need, initially in cancer and neurologic diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-1069% match
“Our mission is to build a leading oncology company that creates novel and transformative treatments for a wide range of oncology indications for which there are significant unmet medical needs.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0768% match
“Our mission is to target cancer and transform lives through the development of innovative cancer treatments.”In use 2005 – now·1 sighting·SEC Form 10-K, filed 2005-03-1668% match
“Our mission is to develop novel treatments for dormant cancers: targeting cancer resistance, metastasis, and relapse.”In use 2022 – now·1 sighting·SEC Form S-1/A, filed 2022-12-0868% match
“Our mission is to inspire hope for those battling cancer by expanding on the promise of targeted therapies.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-1568% match
“Our mission is to become a global leader in developing better and safer radioimmunotherapy and antibody-based oncology therapies addressing clear unmet medical needs and, as such, have a transformational impact on the lives of patients.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-0467% match
“Our mission is to change the landscape of oncology drug discovery and enable the development of more effective therapies for the treatment of cancer.”In use 2025 – now·1 sighting·SEC Form S-1, filed 2025-07-1867% match
“Our mission is to discover and develop novel therapeutics to address significant medical needs.”In use 2007 – now·1 sighting·SEC Form 10-K, filed 2007-03-1967% match
“Our mission is to create therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-04-1667% match
“Our mission is to make a meaningful impact on the lives of patients with cancer and high unmet medical needs by delivering novel, PRAME-directed immunotherapies that provide tangible clinical benefits.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-03-0567% match
“Our mission is to discover and develop a pipeline of EPBs to treat a broad range of diseases and disorders, with an initial focus on cancers with a high unmet medical need.”In use 2022 – now·1 sighting·SEC Form 20-F, filed 2022-04-2667% match
“Our mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of therapeutic agents.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3066% match
“Our mission is to benefit patients by developing and commercializing anti-cancer therapies for patients whose solid tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, with particular focus on orphan cancer indications.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-10-0766% match
“Our mission is to develop a portfolio of innovative product candidates for the treatment of cancer.”In use 2022 – now·1 sighting·SEC Form 424B4, filed 2022-02-0766% match
“Our mission is to become a leader in bringing innovative cancer treatments to the market and to improve patient health outcomes.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2066% match
“Our mission is to accelerate transformative therapies to improve the lives of people living with cancer and other serious diseases.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-02-2366% match
“Our mission is to significantly improve patient outcomes and address areas of high unmet medical need with our nanotechnology-based therapies.”In use 2020 – now·1 sighting·SEC Form 424B4, filed 2020-12-1166% match
“Our mission is to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2466% match
“Our mission is to develop and commercialize novel, non-opioid, and non-addictive therapies to safely and effectively address the significant unmet medical need of chronic pain or treat conditions that cause pain.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-03-3066% match
“Our mission is to develop and commercialize novel, non-opioid and non-addictive therapies to safely and effectively address the significant unmet medical need of chronic pain.”In use 2019 – now·1 sighting·SEC Form S-1/A, filed 2019-12-2366% match
“Our mission is to accelerate scientific and medical breakthroughs and deliver well-tolerated medicines with greater efficacy and safety to people with the deadliest cancers.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0566% match
“Our mission is to revolutionize the treatment of solid tumors with a single dose of engineered TCR T-cells and as a result to address cancers with high unmet needs.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-2466% match
“Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-1766% match
“Our mission is to create and advance new medicines for patients suffering from serious and rare diseases that are underserved by today’s therapies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2665% match
“Our mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-0765% match
“Our mission is to advance and grow a portfolio of innovative, early-stage oncology assets based on the latest scientific breakthroughs focused on overcoming immune resistance and expanding the addressable patient population.”In use 2023 – now·1 sighting·SEC Form 20-F, filed 2023-07-3165% match
“Our mission is to develop and commercialize therapies with the potential to transform the lives of patients and their families living with rare diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-0165% match
“Our mission is to develop innovative therapies that can transform patients' lives by addressing areas of high unmet medical need.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2365% match
“Our mission is to become a leading global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing both first- and best-in-class therapies to address global unmet medical needs primarily in hematological malignancies.”In use 2025 – now·1 sighting·SEC Form 424B4, filed 2025-01-2465% match
“Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-1565% match
“Our mission is to improve the quality of life of people suffering from cancer and to increase shareholder value by commercializing our platform technologies through in-house development, joint ventures, strategic alliances and licensing arrangements.”In use 2003 – now·1 sighting·SEC Form 10-K, filed 2003-07-2965% match
“Our mission is to accelerate the discovery, development and global access to targeted radioligand therapies.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2765% match
“Our mission is to transform cancer treatment by delivering innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining our deep understanding of tumor biology and translational medicine with our expertise in radiochemistry.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3065% match
“Our mission is to develop, register and commercialize safe and effective drugs, with novel mechanisms of action, to meet the major unmet medical needs of patients on a global basis.”In use 2012 – now·1 sighting·SEC Form 10-K, filed 2012-03-1565% match
“Our mission is to create new standards of care for patients with cancer.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-0965% match
“Our mission is to develop treatments for serious diseases.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2265% match
“Our mission is to develop new and effective immune-oncologic therapeutics.”In use 2015 – now·1 sighting·SEC Form 10-K, filed 2015-10-1465% match
“Our mission is to build a community and company capable of sustainably discovering, developing and delivering to patients innovative, important new medicines that will make a material difference in their health, well-being and lives.”In use 2009 – now·1 sighting·SEC Form 10-K, filed 2009-03-1365% match
“Our mission is to change the standard of care for patients with blood cancer by engineering hematopoietic stem cells (“HSCs”) to enable the use of targeted therapies post-transplant.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-03-2364% match
“Our mission is to discover and develop novel therapeutic drugs to treat diseases and disorders for which there are no adequate therapies or for which a new drug would represent a significant advancement over the current therapy.”In use 2003 – now·1 sighting·SEC Form 10-K, filed 2003-03-1464% match
“Our mission is to discover, develop and commercialize novel and transformative therapies that improve the lives of patients with serious diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2264% match
“Our mission is to develop first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other rare disorders.”In use 2020 – now·1 sighting·SEC Form 10-K, filed 2020-03-2764% match
“Our mission is to develop therapeutic products with the potential to address high unmet medical needs by identifying promising clinical-stage candidates and advancing their development to create products that will improve patients’ lives.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2164% match
“Our mission is to expand our portfolio into a wide range of muscle diseases and become a leader in this area by advancing life-transforming therapeutics for patients with serious muscle diseases.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-03-0464% match
Showing 1–50 of 50